Brief: Guard Therapeutics Q4 Operating Loss Narrows To SEK 15.3 Mln
Feb 21 (Reuters) - Guard Therapeutics International AB
(publ) GUARD.ST :
* Q4 OPERATING LOSS SEK 15.3 MILLION VERSUS LOSS SEK 39.8
MILLION
YEAR AGO
* Q4 COSTS FOR RESEARCH AND DEVELOPMENT DECREASED TO SEK
13.0
MILLION VERSUS SEK 38.2 MILLION YEAR AGO
Source text for Eikon: ID:nMFN2wy7PD
Further company coverage: GUARD.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Disruptive Pharma AB (publ)
See all newsBrief: Disruptive Pharma To Sell GTX Platform To Aurelia Invest AB Unit
Brief: Guard Therapeutics International Q2 Loss Before Tax SEK 4.4 Mln
Brief: Guard Therapeutics Gets Conditional Approval For Continued Listing
Brief: Guard Therapeutics International Initiates Deal Process For Gtx Platform
Brief: Guard Therapeutics Enters Conditional Deal For Reverse Takeover